<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133978</url>
  </required_header>
  <id_info>
    <org_study_id>REDOXS</org_study_id>
    <secondary_id>EudraCT-No: 2007-001831-73</secondary_id>
    <nct_id>NCT00133978</nct_id>
  </id_info>
  <brief_title>Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients</brief_title>
  <acronym>REDOXS</acronym>
  <official_title>REducing Deaths Due to OXidative Stress The REDOXSÂ© Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daren K. Heyland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Evaluation Research Unit at Kingston General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether providing high dose glutamine and
      antioxidants to critically ill patients will be associated with improved survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Critically ill patients experience a degree of hyperinflammation, cellular immune
      dysfunction, and oxidative stress. Supplementation with key nutrients, like glutamine and
      antioxidants, is most likely to have a favourable effect on these physiological parameters
      leading to an improvement in clinical outcomes. The results of two separate meta-analyses
      suggested that glutamine and antioxidants may be associated with improved survival. We have
      recently completed a dosing study to determine the maximal tolerable dose (MTD) of glutamine
      dipeptides and antioxidants in critically ill patients with evidence of hypoperfusion. The
      purpose of this protocol is to evaluate the effect of high dose glutamine and antioxidant
      supplementation on mortality in a large scale randomized trial.

      Study Intervention:

      Patients will be randomized to receive glutamine supplementation or antioxidant
      supplementation (or respective placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>28-day mortality/status: at 28 days after randomization;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>Day 28</time_frame>
    <description>Measure of the duration of participant stay in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Acquired Infection</measure>
    <time_frame>Day 28</time_frame>
    <description>We have made some modifications the definitions developed by the International Sepsis Forum Consensus Conference (CCM 2005;33:1538-1548) to operationalize the adjudication of infections in this trial. We grade the certainty of the diagnosis of infection using definitions for 'Definite', 'Probable', and 'Possible' for each category of infection. The categories of infection are: Deep surgical wound infection, Incisional (or superficial) surgical wound infection, Skin and soft-tissue infection (non-surgical) (SSTS), Catheter-related blood stream infections (CRI), Primary blood stream infections (BSI), Lower urinary tract infection, Upper urinary tract infection, Intra abdominal infection, Sinusitis, Lower respiratory tract infection (excluding pneumonia), ICU Acquired Pneumonia and Other.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>6 months (from ICU admission)</time_frame>
    <description>Measure of the duration of the participant's hospital stay</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1223</enrollment>
  <condition>Critical Illness</condition>
  <condition>Sepsis</condition>
  <condition>Multiple Organ Failure</condition>
  <arm_group>
    <arm_group_label>Glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glutamine supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antioxidant supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glutamine + Antioxidants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glutamine and antioxidant supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-isonitrogenic, iso-caloric placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>0.35 gm/kg/day parenterally and 30 gms/day enterally</description>
    <arm_group_label>Glutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antioxidants</intervention_name>
    <description>500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally</description>
    <arm_group_label>Antioxidants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glutamine + Antioxidants</intervention_name>
    <description>0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg</description>
    <arm_group_label>Glutamine + Antioxidants</arm_group_label>
    <other_name>Dipeptiven, Microselenium/Selenium injection/selenase, EN REDOX formula (from Fresenius Kabi, Germany)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mechanically ventilated patients &gt; or = 18 years old

          -  2 or more organ failures related to acute illness

        Exclusion Criteria:

          -  &gt; 24 hours from admission to ICU

          -  Patients who are moribund

          -  Lack of commitment to aggressive care

          -  Absolute contraindication to enteral nutrients

          -  Severe acquired brain injury

          -  Routine elective cardiac surgery

          -  Primary admission of burns &gt; 30% body surface area

          -  Weight &lt; 50 kgms or &gt; 200 kgms

          -  Pregnant or lactating patients

          -  Previous randomization in this study

          -  Enrollment in a related ICU interventional study

          -  Child's class C liver disease

          -  Metastatic cancer with life expectancy &lt; 6 months

          -  Seizure disorder requiring anticonvulsant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daren Heyland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Evaluation Research Unit, Kingston General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Colorado at Denver and Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>6431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allan Centre</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nun's Hospital, Edmonton</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Jubilee Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria General Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8Z 6R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health Queen Elizabeth II HSC</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London HSC Victoria Campus, ON</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Civic Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook &amp; Women's College, Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemount</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Sacre-Coeur</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enfant-Jesus</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum der Ernst-Moritz-Arndt-Universitat</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken Hamburg Altona</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein Campus Luebeck</name>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>Ch-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=19&amp;Itemid=42</url>
    <description>Click here for more information about this study: A Randomized Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients</description>
  </link>
  <reference>
    <citation>Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P; Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr. 2003 Sep-Oct;27(5):355-73.</citation>
    <PMID>12971736</PMID>
  </reference>
  <reference>
    <citation>Heyland DK, Dhaliwal R, Suchner U, Berger MM. Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Med. 2005 Mar;31(3):327-37. Epub 2004 Dec 17. Review.</citation>
    <PMID>15605227</PMID>
  </reference>
  <reference>
    <citation>Novak F, Heyland DK, Avenell A, Drover JW, Su X. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med. 2002 Sep;30(9):2022-9. Review.</citation>
    <PMID>12352035</PMID>
  </reference>
  <results_reference>
    <citation>Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG; Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013 Apr 18;368(16):1489-97. doi: 10.1056/NEJMoa1212722. Erratum in: N Engl J Med. 2013 May 9;368(19):1853. Dosage error in article text..</citation>
    <PMID>23594003</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <results_first_submitted>April 29, 2013</results_first_submitted>
  <results_first_submitted_qc>August 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2014</results_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Evaluation Research Unit at Kingston General Hospital</investigator_affiliation>
    <investigator_full_name>Daren K. Heyland</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>randomized trial</keyword>
  <keyword>antioxidants</keyword>
  <keyword>glutamine</keyword>
  <keyword>organ failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted between April 2005 and December 2011 in 40 ICUs in participating countries after local jurisdictional and institutional Research Ethics Board approval.</recruitment_details>
      <pre_assignment_details>Written informed consent was obtained from patients or their legal representatives before enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glutamine</title>
          <description>Glutamine supplementation 0.35 g/kg/day of glutamine intravenously based on ideal body weight, provided as 0.50 g/kg/day of the dipeptide alanyl-glutamine and 30 g/day enterally, provided as alanyl-glutamine and glycine-glutamine dipeptides.</description>
        </group>
        <group group_id="P2">
          <title>Antioxidants</title>
          <description>Antioxidant supplementation 500 ug of selenium intravenously, and the following vitamins and minerals enterally-- selenium 300 ï­g, zinc 20 mg, beta carotene 10 mg, vitamin E 500 mg, and vitamin C 1500 mg.</description>
        </group>
        <group group_id="P3">
          <title>Glutamine + Antioxidants</title>
          <description>Glutamine and antioxidant supplementation 0.35 g/kg/day of glutamine intravenously based on ideal body weight, provided as 0.50 g/kg/day of the dipeptide alanyl-glutamine and 30 g/day enterally, provided as alanyl-glutamine and glycine-glutamine dipeptides.
500 ug of selenium intravenously , and the following vitamins and minerals enterally-- selenium 300 ï­g, zinc 20 mg, beta carotene 10 mg, vitamin E 500 mg, and vitamin C 1500 mg.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Non-isonitrogenic, iso-caloric placebo solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="308"/>
                <participants group_id="P3" count="310"/>
                <participants group_id="P4" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="307"/>
                <participants group_id="P3" count="310"/>
                <participants group_id="P4" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Five randomized patients were not evaluable because we could not ascertain their 28-day vital status leaving 1218 patients in the final intention-to-treat analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Glutamine</title>
          <description>Glutamine supplementation</description>
        </group>
        <group group_id="B2">
          <title>Antioxidants</title>
          <description>Antioxidant supplementation</description>
        </group>
        <group group_id="B3">
          <title>Glutamine + Antioxidants</title>
          <description>Glutamine and antioxidant supplementation</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Non-isonitrogenic, iso-caloric placebo solution</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
            <count group_id="B2" value="307"/>
            <count group_id="B3" value="310"/>
            <count group_id="B4" value="300"/>
            <count group_id="B5" value="1218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="159"/>
                    <measurement group_id="B5" value="621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="15.0"/>
                    <measurement group_id="B2" value="63.6" spread="14.3"/>
                    <measurement group_id="B3" value="64.3" spread="14.0"/>
                    <measurement group_id="B4" value="62.8" spread="13.7"/>
                    <measurement group_id="B5" value="63.3" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="178"/>
                    <measurement group_id="B5" value="726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="263"/>
                    <measurement group_id="B4" value="260"/>
                    <measurement group_id="B5" value="1044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>28-day Mortality</title>
        <description>28-day mortality/status: at 28 days after randomization;</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>Glutamine supplementation</description>
          </group>
          <group group_id="O2">
            <title>Antioxidants</title>
            <description>Antioxidant supplementation</description>
          </group>
          <group group_id="O3">
            <title>Glutamine + Antioxidants</title>
            <description>Glutamine and antioxidant supplementation</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-isonitrogenic, iso-caloric placebo solution</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Mortality</title>
          <description>28-day mortality/status: at 28 days after randomization;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="310"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay</title>
        <description>Measure of the duration of participant stay in the ICU</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>Glutamine supplementation</description>
          </group>
          <group group_id="O2">
            <title>Antioxidants</title>
            <description>Antioxidant supplementation</description>
          </group>
          <group group_id="O3">
            <title>Glutamine + Antioxidants</title>
            <description>Glutamine and antioxidant supplementation</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-isonitrogenic, iso-caloric placebo solution</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <description>Measure of the duration of participant stay in the ICU</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="310"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="5.6" upper_limit="16.0"/>
                    <measurement group_id="O2" value="8.9" lower_limit="4.8" upper_limit="15.6"/>
                    <measurement group_id="O3" value="8.9" lower_limit="5.0" upper_limit="15.1"/>
                    <measurement group_id="O4" value="8.3" lower_limit="4.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Acquired Infection</title>
        <description>We have made some modifications the definitions developed by the International Sepsis Forum Consensus Conference (CCM 2005;33:1538-1548) to operationalize the adjudication of infections in this trial. We grade the certainty of the diagnosis of infection using definitions for âDefiniteâ, âProbableâ, and âPossibleâ for each category of infection. The categories of infection are: Deep surgical wound infection, Incisional (or superficial) surgical wound infection, Skin and soft-tissue infection (non-surgical) (SSTS), Catheter-related blood stream infections (CRI), Primary blood stream infections (BSI), Lower urinary tract infection, Upper urinary tract infection, Intra abdominal infection, Sinusitis, Lower respiratory tract infection (excluding pneumonia), ICU Acquired Pneumonia and Other.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>0.35 g/kg/day of glutamine intravenously based on ideal body weight, provided as 0.50 g/kg/day of the dipeptide alanyl-glutamine and 30 g/day enterally, provided as alanyl-glutamine and glycine-glutamine dipeptides.</description>
          </group>
          <group group_id="O2">
            <title>No Glutamine</title>
            <description>Non-isonitrogenic, iso-caloric placebo solution</description>
          </group>
          <group group_id="O3">
            <title>Antioxidants</title>
            <description>500 ug of selenium intravenously and the following vitamins and minerals enterally-- selenium 300 ug, zinc 20 mg, beta carotene 10 mg, vitamin E 500 mg, and vitamin C 1500 mg.</description>
          </group>
          <group group_id="O4">
            <title>No Antioxidants</title>
            <description>Non-isonitrogenic, iso-caloric placebo solution</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Acquired Infection</title>
          <description>We have made some modifications the definitions developed by the International Sepsis Forum Consensus Conference (CCM 2005;33:1538-1548) to operationalize the adjudication of infections in this trial. We grade the certainty of the diagnosis of infection using definitions for âDefiniteâ, âProbableâ, and âPossibleâ for each category of infection. The categories of infection are: Deep surgical wound infection, Incisional (or superficial) surgical wound infection, Skin and soft-tissue infection (non-surgical) (SSTS), Catheter-related blood stream infections (CRI), Primary blood stream infections (BSI), Lower urinary tract infection, Upper urinary tract infection, Intra abdominal infection, Sinusitis, Lower respiratory tract infection (excluding pneumonia), ICU Acquired Pneumonia and Other.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="611"/>
                <count group_id="O2" value="607"/>
                <count group_id="O3" value="617"/>
                <count group_id="O4" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="168"/>
                    <measurement group_id="O4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections classified as 'definite' or 'probable'</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Microbiological Confirmed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Measure of the duration of the participant's hospital stay</description>
        <time_frame>6 months (from ICU admission)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>Glutamine supplementation</description>
          </group>
          <group group_id="O2">
            <title>Antioxidants</title>
            <description>Antioxidant supplementation</description>
          </group>
          <group group_id="O3">
            <title>Glutamine + Antioxidants</title>
            <description>Glutamine and antioxidant supplementation</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-isonitrogenic, iso-caloric placebo solution</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Measure of the duration of the participant's hospital stay</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="310"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="9.0" upper_limit="35.1"/>
                    <measurement group_id="O2" value="16.0" lower_limit="8.0" upper_limit="31.4"/>
                    <measurement group_id="O3" value="16.9" lower_limit="8.2" upper_limit="37.0"/>
                    <measurement group_id="O4" value="16.5" lower_limit="7.2" upper_limit="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>April 2005 and December 2011</time_frame>
      <desc>We collect data related to these hospitalized, critically ill patients' baseline illness in the CRF (e.g. abnormalities in oxygenation or ventilation, hemodynamic measures, etc). We reported changes in patients' baseline condition, events that are inconsistent with the underlying pathophysiology or progression of underlying disease, as SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glutamine</title>
          <description>Glutamine supplementation 0.35 g/kg/day of glutamine intravenously based on ideal body weight, provided as 0.50 g/kg/day of the dipeptide alanyl-glutamine and 30 g/day enterally, provided as alanyl-glutamine and glycine-glutamine dipeptides.</description>
        </group>
        <group group_id="E2">
          <title>Antioxidants</title>
          <description>Antioxidant supplementation 500 ug of selenium intravenously and the following vitamins and minerals enterally-- selenium 300 ug, zinc 20 mg, beta carotene 10 mg, vitamin E 500 mg, and vitamin C 1500 mg.</description>
        </group>
        <group group_id="E3">
          <title>Glutamine + Antioxidants</title>
          <description>Glutamine and antioxidant supplementation 0.35 g/kg/day of glutamine intravenously based on ideal body weight, provided as 0.50 g/kg/day of the dipeptide alanyl-glutamine and 30 g/day enterally, provided as alanyl-glutamine and glycine-glutamine dipeptides.
500 ug of selenium intravenously and the following vitamins and minerals enterally-- selenium 300 ug, zinc 20 mg, beta carotene 10 mg, vitamin E 500 mg, and vitamin C 1500 mg.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Non-isonitrogenic, iso-caloric placebo solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="310"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="301"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="310"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="310"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="301"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="310"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Procedural Complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daren Heyland</name_or_title>
      <organization>Clinical Evaluation Research Unit</organization>
      <phone>613-549-6666 ext 4847</phone>
      <email>dkh2@queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

